LLY Lilly (Eli)

Q1 2025 10-Q

Filed: May 1, 2025Period ending Mar 31, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Lilly (Eli) (LLY) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Management Discussion & Analysis

• Cash and cash equivalents $3.09B as of Mar 31, 2025 vs $3.27B Dec 31, 2024
• Total debt $38.52B up $4.87B from $33.64B Dec 31, 2024, driven by $6.5B notes issued and Scorpion acquisition

+3 more insights

Risk Factors

• New acquisition risk: $1,571.7 million acquired IPR&D charge from Scorpion PI3Kα inhibitor program STX-478 acquisition
• Updated tax risk: effective tax rate increased to 20.2% from 11.6%, driven by non-deductible acquired IPR&D charge

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$12.7B

▲ +45.2% YoY

Net Income

$2.8B

▲ +23.0% YoY

Net Margin

21.7%

▼ -390bp YoY

Source: XBRL data from Lilly (Eli) Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Lilly (Eli) Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Lilly (Eli)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.